An article from
News roundup
An arbitration panel ruled Prime didn’t breach a 2019 deal with Beam. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for reviews.
Published July 8, 2026
Getty Images
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for reviews.
539 words~2 min read
